IMUX
IMMUNIC, INC.
NASDAQ · Healthcare · Biotechnology · US
$10.62
+2.61%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$10.30
From 52W high−37.16%
Volume403557.00
Market cap$144.90M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$10.30
From 52W high
−37.16%
Volume
403557.00
Market cap
$144.90M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
24.7
MomentumView details →
1D Return
+2.61%
YTD Return
+93.45%
SummaryUpdated Jun 1, 2026
Immunic, Inc. (NASDAQ:IMUX) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York, New York. The company went public in April 2014 and focuses on developing selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases. Immunic operates as a research-focused organization with no current revenue-generating products, instead investing heavily in clinical trials to advance its pipeline of experimental treatments through various phases of regulatory approval.
Similar companies
Latest newsMore news →
Duane Nash resigned as a member of the Board of Directors of Immunic, Inc., effective September 10, 2026.9d agoImmunic Inc announced it will host a virtual R&D day on September 9, 2026, focused on relapsing multiple sclerosis, ahead of expected topline results from its Phase 3 ENSURE trials by end of 2026.18d ago